<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hoenigl M</submitter><funding>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)</funding><funding>NOVA | Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa</funding><funding>U.S. Department of Health &amp;amp; Human Services | NIH | National Institute of Allergy and Infectious Diseases</funding><funding>NIAID NIH HHS</funding><funding>EC | Horizon 2020 Framework Programme</funding><pagination>1127-1140</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9362108</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7(8)</volume><pubmed_abstract>Coronavirus disease 2019 (COVID-19)-associated invasive fungal infections are an important complication in a substantial number of critically ill, hospitalized patients with COVID-19. Three groups of fungal pathogens cause co-infections in COVID-19: Aspergillus, Mucorales and Candida species, including Candida auris. Here we review the incidence of COVID-19-associated invasive fungal infections caused by these fungi in low-, middle- and high-income countries. By evaluating the epidemiology, clinical risk factors, predisposing features of the host environment and immunological mechanisms that underlie the pathogenesis of these co-infections, we set the scene for future research and development of clinical guidance.</pubmed_abstract><journal>Nature microbiology</journal><pubmed_title>COVID-19-associated fungal infections.</pubmed_title><pmcid>PMC9362108</pmcid><funding_grant_id>R01 AI153356</funding_grant_id><funding_grant_id>PTDC/SAU-SER/29635/2017</funding_grant_id><funding_grant_id>R01AI153356</funding_grant_id><funding_grant_id>UIDB/50026/2020 and UIDP/50026/2020</funding_grant_id><funding_grant_id>R01AI063503</funding_grant_id><funding_grant_id>no. 847507</funding_grant_id><pubmed_authors>Carvalho A</pubmed_authors><pubmed_authors>Goldman GH</pubmed_authors><pubmed_authors>Sprute R</pubmed_authors><pubmed_authors>Ibrahim AS</pubmed_authors><pubmed_authors>Seidel D</pubmed_authors><pubmed_authors>Oliverio M</pubmed_authors><pubmed_authors>Hoenigl M</pubmed_authors><pubmed_authors>Cunha C</pubmed_authors></additional><is_claimable>false</is_claimable><name>COVID-19-associated fungal infections.</name><description>Coronavirus disease 2019 (COVID-19)-associated invasive fungal infections are an important complication in a substantial number of critically ill, hospitalized patients with COVID-19. Three groups of fungal pathogens cause co-infections in COVID-19: Aspergillus, Mucorales and Candida species, including Candida auris. Here we review the incidence of COVID-19-associated invasive fungal infections caused by these fungi in low-, middle- and high-income countries. By evaluating the epidemiology, clinical risk factors, predisposing features of the host environment and immunological mechanisms that underlie the pathogenesis of these co-infections, we set the scene for future research and development of clinical guidance.</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2025-04-04T10:45:01.082Z</modification><creation>2025-04-04T10:45:01.082Z</creation></dates><accession>S-EPMC9362108</accession><cross_references><pubmed>35918423</pubmed><doi>10.1038/s41564-022-01172-2</doi></cross_references></HashMap>